Eli Lilly Inks Multibillion-Dollar Pact to Develop Precision Cancer Therapies
Eli Lilly partners with Stipple Bio in a $5.9B licensing deal to develop targeted cancer treatments using its Pointillist Platform.
Last updated: 2026-11-17 22:51:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Eli Lilly & Co. (LLY) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $1,415.14, with a market capitalization of $1.29T and a P/E ratio of 46.24. Over the past 52 weeks, its price has ranged from $850.51 to $1,475.25. This page covers its latest market performance, valuation, price trends and company information.
$1.29T | |
$1,416.00 | |
$1,439.03 | |
$1,402.34 | |
$1,431.67 | |
1.95M | |
2.60M | |
46.24 | |
$1,475.25 | |
$850.51 | |
0.47% | |
12-31 |
Eli Lilly & Co. (LLY) is trading at $1,409.47 in after-hours trading as of 2026-11-17 22:34:05, down 0.40% ($5.67) from the regular-session close of $1,415.14.
After-hours trading shows how investors are pricing LLY after the regular session closes. The current after-hours price is near the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Eli Lilly & Co. (LLY) moved from $1,354.00 to $1,415.14, representing a gain of 4.52% ($61.14).
The stock traded between $1,333.22 and $1,475.25 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 2.92 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 90.4%
LLY is currently trading at $1,415.14, placing it 90.4% of the way from its 52-week low of $850.51 to its 52-week high of $1,475.25. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 50,000 |
| CEO | David A. Ricks |
| Founded | 1876 |
| Exchange | NYSE |
| Company Website |
View the latest dividend and stock split events for Eli Lilly & Co.
Dividend | |
|---|---|
| Ex-Dividend Date | Nov 13, 2026 |
| Payment Date | Dec 10, 2026 |
| Dividend Per Share | $1.73 |
Latest news related to Eli Lilly & Co. and LLY stock.
Eli Lilly partners with Stipple Bio in a $5.9B licensing deal to develop targeted cancer treatments using its Pointillist Platform.
Eli Lilly and Co. (NYSE:LLY) short sellers added to their positions, with the latest report following the company’s Q3 2026 earnings release.Short interest rose 3.64% to 7.21 million shares as of the Oct. 30 settlement
The American Academy of Sleep Medicine released a comprehensive report and multiyear roadmap to improve women's sleep health, identifying priority areas including fertility, pregnancy, postpartum health, menopausal transitions, and sleep disorders. The report highlights gaps in research, clinical care, and policy, calling for increased clinical trial representation, research funding, and tailored interventions for women.
The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.
RBC Capital analyst Trung Huynh reiterates Eli Lilly (NYSE:LLY) with a Outperform and maintains $1600 price target.
Eligible investors can buy real shares of Eli Lilly & Co. (LLY) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to LLY, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between LLY shares and USD.
LLY Shares to USD
1.00 LLY shares = 1,415.138 USD
Calculations are estimates based on the latest available price and are for reference only.